TScan Therapeutics Announces Poster Presentations at the American Society of Hematology’s 63rd Annual Convention and Exhibition

– Posters highlight TSC-101 discovery, manufacturing process, and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 –

Phase 1 clinical trial expected to start in the first half of 2021 –

– Company to host KOL virtual event on Wednesday, December 15 at 4:30 p.m. ET –

WALTHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) – TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on developing T cell receptor (TCR) engineered T cell therapies (TCR-T.) Concentrated) for the Treatment of Cancer Patients, today announced the presentation of two posters for its leading liquid tumor candidates, TSC-100 and TSC-101. The posters were shown at the 63approx American Society of Hematology (ASH) annual meeting and exhibition. TSC-100 and TSC-101 are TCR-T cell products that are directed against the minor histocompatibility antigens HA-1 and HA-2, which are only found on blood cells. TScan develops these products to prevent relapse after a hematopoietic cell transplant (HCT) in myeloid leukemia. The company plans to submit new drug review requests (INDs) for both programs before the end of 2021. A copy of each poster is available on TScan’s website at http://www.tscan.com/technology/publications/.

As previously announced, the company’s poster presentations will include:

Title: Product features and multi-arm clinical trial design for TSC-100 and TSC-101, TRG-T cells targeting leukemia after hematopoietic cell transplantation
Moderator: Shrikanta Chattopadhyay, MD, MBBS, TScan Therapeutics
Author: Chattopadhyay et al.
Poster number: 3863
Meeting: Cellular Immunotherapies: Clinical

Title: Discovery of TSC-101: A world-class natural HA-2-specific TCR for the treatment of leukemia following haematopoietic stem cell transplant therapy
Moderator: Gavin MacBeath, Ph.D., TScan Therapeutics
Author: Nayar et al.
Poster number: 1704
Meeting: Cellular Immunotherapies: Basic and Translational

Webcast details

The company will host a webcast on Wednesday, December 15, 2021 at 4:30 p.m. ET. The event provides a summary of the ASH posters, including the planned clinical trial design for the TSC-100 and TSC-101. Additionally, Yi-Bin Chen, MD, MS, Director, Hematopoietic Cell Transplantation and Cell Therapy Program, Allan B. Rogers, Jr. and Cara J. Rogers Endowed Chair, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, will provide details on the provide the current standard of care. The presentation is followed by a question-and-answer session.

The live audio webcast and accompanying slides can be accessed from the Events and Presentations page in the Investor section of the company’s website at www.tscan.com. You can register for the event here. For those unable to attend the live webcast, a replay will be available in the investor section of the company’s website at https://ir.tscan.com/news-events/events-and-presentations.

About TScan Therapeutics, Inc.

TScan is a biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of cancer patients. The Company’s leading liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eradicate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplex TCR-T therapy candidates for the treatment of a variety of solid tumors.

Forward-Looking Statements

This press release may contain forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may”, “will”, “could”, “should”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict” “projects.” “,” Strive, “” Endeavor, “” Potential, “” Further, “or the negative of such words or other similar expressions may be used to identify forward-looking statements. Forward-looking statements, express or implied, in this press release are made only as predictions and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, the risks set out under the headings “Risk Factors” and “Management Discussion and Analysis of Financial Condition and Results of Operations “TScan’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission (SEC) and available on the SEC’s website at https: // www.sec.gov Given these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not materialize, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely on any forward-looking statements a ls rely on predictions of future events. Although TScan believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, activities, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. Furthermore, neither TScan nor any other person accepts responsibility for the accuracy or completeness of the forward-looking statements in this press release, except as required by law. All forward-looking statements in this press release speak only as of the date of its publication. We undertake no obligation to publicly update or revise any forward-looking statements as a result of new information, future events or for any other reason, except as required by law.

contacts

TScan therapeutics
Heath Savelle
VP, Investor Relations
857-399-9840
[email protected]

Media contact:
David Rosen
Argot partner
212-600-1902
[email protected]

Investor contact:
Sherri Speer
Argot partner
212-600-1902
[email protected]


Source link

Comments are closed.